Biotechnology stocks
268 US-listed companies in biotechnology, with $229.8bn of combined revenue in their latest fiscal years. AbbVie is the largest ($61.2bn). The fastest grower with at least $100m of revenue in both years is Madrigal Pharmaceuticals, Inc., up 432.1%. The median company grew 20.8% with a net margin of −4.3%.
Companies268
Combined revenue$229.8bn
Median revenue growth20.8%
Median net margin−4.3%
Median return on equity−1.4%
| # | Company | Revenue | Growth | Net margin | ROE | Fiscal year |
|---|---|---|---|---|---|---|
| 1 | AbbVieABBV | $61.2bn | 8.6% | 6.9% | — | 2025 |
| 2 | AmgenAMGN | $36.8bn | 10.0% | 21.0% | 106.1% | 2025 |
| 3 | Gilead SciencesGILD | $29.4bn | 2.4% | 28.9% | 40.5% | 2025 |
| 4 | Regeneron PharmaceuticalsREGN | $14.3bn | 1.0% | 31.4% | 14.9% | 2025 |
| 5 | Vertex PharmaceuticalsVRTX | $12.0bn | 8.9% | 32.9% | 22.5% | 2025 |
| 6 | BiogenBIIB | $9.9bn | 2.2% | 13.1% | 7.4% | 2025 |
| 7 | IncyteINCY | $5.1bn | 21.2% | 25.0% | 29.9% | 2025 |
| 8 | Argenx SEARGX | $4.2bn | 89.9% | 31.1% | 20.2% | 2025 |
| 9 | Alnylam Pharmaceuticals, Inc.ALNY | $3.7bn | 65.2% | 8.4% | 73.3% | 2025 |
| 10 | Biontech SEBNTX | $3.2bn | 9.0% | −39.6% | −6.0% | 2025 |
| 11 | Biomarin Pharmaceutical IncBMRN | $3.2bn | 12.9% | 10.8% | 5.9% | 2025 |
| 12 | United Therapeutics CorpUTHR | $3.2bn | 10.6% | 41.9% | 19.7% | 2025 |
| 13 | Neurocrine Biosciences IncNBIX | $2.9bn | 21.4% | 16.7% | 16.4% | 2025 |
| 14 | Exelixis, Inc.EXEL | $2.3bn | 7.0% | 33.7% | 35.5% | 2025 |
| 15 | Natera, Inc.NTRA | $2.3bn | 35.9% | −9.0% | −14.3% | 2025 |
| 16 | Sarepta Therapeutics, Inc.SRPT | $2.2bn | 15.6% | −32.5% | −53.5% | 2025 |
| 17 | ModernaMRNA | $1.9bn | −39.9% | −145.2% | −28.9% | 2025 |
| 18 | PTC Therapeutics, Inc.PTCT | $1.7bn | 114.5% | 39.4% | — | 2025 |
| 19 | Alkermes plc.ALKS | $1.5bn | −5.2% | 16.4% | 14.7% | 2025 |
| 20 | Halozyme Therapeutics, Inc.HALO | $1.4bn | 37.6% | 22.7% | 153.6% | 2025 |
| 21 | Lakefront Biotherapeutics NVLKFT | $1.3bn | 321.6% | 28.9% | 10.7% | 2025 |
| 22 | Novavax IncNVAX | $1.1bn | 64.7% | 39.2% | — | 2025 |
| 23 | Acadia Pharmaceuticals IncACAD | $1.1bn | 11.9% | 36.5% | 39.9% | 2025 |
| 24 | Legend Biotech CorpLEGN | $1.0bn | 64.0% | −28.8% | −29.1% | 2025 |
| 25 | Madrigal Pharmaceuticals, Inc.MDGL | $958m | 432.1% | −30.1% | −42.5% | 2025 |
| 26 | Ionis Pharmaceuticals IncIONS | $944m | 33.8% | −40.4% | −70.8% | 2025 |
| 27 | Biocryst Pharmaceuticals IncBCRX | $875m | 94.1% | 30.2% | — | 2025 |
| 28 | Arrowhead Pharmaceuticals, Inc.ARWR | $829m | 23258.2% | −0.2% | −0.5% | 2025 |
| 29 | Ascendis Pharma A/sASND | $814m | 106.9% | −31.7% | — | 2025 |
| 30 | Telix Pharmaceuticals LtdTLX | $804m | 55.6% | −0.9% | −1.9% | 2025 |
| 31 | Kiniksa Pharmaceuticals International, plcKNSA | $678m | 60.1% | 8.7% | 11.7% | 2025 |
| 32 | Ultragenyx Pharmaceutical Inc.RARE | $673m | 20.2% | −85.4% | — | 2025 |
| 33 | TG Therapeutics, Inc.TGTX | $616m | 87.3% | 72.6% | 102.8% | 2025 |
| 34 | Insmed IncINSM | $606m | 66.7% | −210.5% | — | 2025 |
| 35 | Hutchmed (china) LtdHCM | $549m | −13.0% | 83.3% | 45.7% | 2025 |
| 36 | Mirum Pharmaceuticals, Inc.MIRM | $521m | 54.7% | −4.5% | −8.6% | 2025 |
| 37 | Adma Biologics, Inc.ADMA | $510m | 19.6% | 28.8% | 35.6% | 2025 |
| 38 | Bridgebio Pharma, Inc.BBIO | $502m | 126.3% | −144.4% | — | 2025 |
| 39 | Tarsus Pharmaceuticals, Inc.TARS | $451m | 146.7% | −14.7% | −23.4% | 2025 |
| 40 | Ardelyx, Inc.ARDX | $407m | 22.1% | −15.1% | −36.2% | 2025 |
| 41 | Krystal Biotech, Inc.KRYS | $389m | 33.9% | 52.6% | 18.9% | 2025 |
| 42 | Sinovac Biotech LTDSVA | $386m | 6.8% | −15.5% | −0.9% | 2025 |
| 43 | Pharming Group N.V.PHAR | $376m | 26.6% | 0.8% | 1.1% | 2025 |
| 44 | Arcutis Biotherapeutics, Inc.ARQT | $376m | 91.3% | −4.3% | −9.3% | 2025 |
| 45 | Mannkind CorpMNKD | $349m | 22.2% | 1.7% | — | 2025 |
| 46 | Moolec Science SAMLEC | $334m | −28.5% | −33.4% | — | 2025 |
| 47 | Cormedix Inc.CRMD | $312m | 617.0% | 52.3% | 66.6% | 2025 |
| 48 | Aurinia Pharmaceuticals Inc.AUPH | $283m | 20.4% | 101.5% | 59.9% | 2025 |
| 49 | Adaptive Biotechnologies CorpADPT | $277m | 54.8% | −21.5% | −28.2% | 2025 |
| 50 | Vericel CorpVCEL | $276m | 16.5% | 6.0% | 5.1% | 2025 |
| 51 | Ligand Pharmaceuticals IncLGND | $268m | 60.4% | 46.4% | 13.5% | 2025 |
| 52 | Iovance Biotherapeutics, Inc.IOVA | $264m | 60.6% | −148.4% | −55.5% | 2025 |
| 53 | Arvinas, Inc.ARVN | $263m | −0.3% | −30.8% | −16.2% | 2025 |
| 54 | Arcus Biosciences, Inc.RCUS | $247m | −4.3% | −142.9% | −63.3% | 2025 |
| 55 | Keros Therapeutics, Inc.KROS | $244m | 6769.4% | 35.7% | 19.9% | 2025 |
| 56 | Akebia Therapeutics, Inc.AKBA | $236m | 47.5% | −2.3% | — | 2025 |
| 57 | Anaptysbio, IncANAB | $235m | 157.0% | −5.6% | −24.5% | 2025 |
| 58 | Puma Biotechnology, Inc.PBYI | $228m | −0.9% | 13.6% | 28.0% | 2025 |
| 59 | Ideaya Biosciences, Inc.IDYA | $219m | 3024.4% | −52.0% | −10.9% | 2025 |
| 60 | Valneva SEVALN | $197m | 7.6% | −66.0% | −83.4% | 2025 |
| 61 | Rhythm Pharmaceuticals, Inc.RYTM | $190m | 45.8% | −103.6% | — | 2025 |
| 62 | Stoke Therapeutics, Inc.STOK | $184m | 404.5% | −3.7% | −2.4% | 2025 |
| 63 | Phathom Pharmaceuticals, Inc.PHAT | $175m | 216.9% | −126.3% | — | 2025 |
| 64 | Syndax Pharmaceuticals IncSNDX | $172m | 627.8% | −165.6% | −161.8% | 2025 |
| 65 | Regenxbio Inc.RGNX | $170m | 104.5% | −113.8% | −107.0% | 2025 |
| 66 | Ginkgo Bioworks Holdings, Inc.DNA | $170m | −25.1% | −183.8% | −51.1% | 2025 |
| 67 | Macrogenics IncMGNX | $150m | −0.3% | −49.9% | −86.9% | 2025 |
| 68 | Karyopharm Therapeutics Inc.KPTI | $146m | 0.6% | −134.2% | — | 2025 |
| 69 | Beam Therapeutics Inc.BEAM | $140m | 120.0% | −57.2% | −8.1% | 2025 |
| 70 | Xencor IncXNCR | $126m | 13.7% | −73.2% | −14.0% | 2025 |
| 71 | Monte Rosa Therapeutics, Inc.GLUE | $124m | 63.5% | −31.2% | −16.9% | 2025 |
| 72 | Atara Biotherapeutics, Inc.ATRA | $121m | −6.3% | 27.1% | — | 2025 |
| 73 | Mesoblast LTDMESO | $120m | 599.2% | −47.8% | −9.9% | 2026 |
| 74 | Agenus IncAGEN | $114m | 10.4% | −0.1% | — | 2025 |
| 75 | Immunitybio, Inc.IBRX | $113m | 668.3% | −310.2% | — | 2025 |
| 76 | Urogen Pharma Ltd.URGN | $110m | 21.4% | −139.8% | — | 2025 |
| 77 | Century Therapeutics, Inc.IPSC | $109m | 1556.8% | −8.8% | −6.0% | 2025 |
| 78 | Zymeworks Inc.ZYME | $106m | 38.9% | −76.6% | −26.7% | 2025 |
| 79 | Sutro Biopharma, Inc.STRO | $102m | 65.2% | −186.5% | — | 2025 |
| 80 | Siga Technologies IncSIGA | $95m | −31.8% | 24.6% | 11.2% | 2025 |
| 81 | Cytokinetics IncCYTK | $88m | 376.6% | −891.6% | — | 2025 |
| 82 | 4d Molecular Therapeutics, Inc.FDMT | $85m | 230194.6% | −164.4% | −27.6% | 2025 |
| 83 | ARS Pharmaceuticals, Inc.SPRY | $84m | −5.5% | −203.3% | −92.3% | 2025 |
| 84 | Nurix Therapeutics, Inc.NRIX | $84m | 54.0% | −314.9% | −49.6% | 2025 |
| 85 | Arcturus Therapeutics Holdings Inc.ARCT | $82m | −46.1% | −80.2% | −28.9% | 2025 |
| 86 | Meiragtx Holdings plcMGTX | $81m | 144.6% | −140.3% | — | 2025 |
| 87 | ADC Therapeutics SAADCT | $81m | 14.9% | −175.3% | — | 2025 |
| 88 | Ascentage Pharma Group InternationalAAPG | $80m | −41.4% | −216.5% | −153.3% | 2025 |
| 89 | Cytomx Therapeutics, Inc.CTMX | $76m | −44.8% | −22.8% | −35.2% | 2025 |
| 90 | Autolus Therapeutics plcAUTL | $75m | 644.9% | −381.4% | −95.0% | 2025 |
| 91 | Abcellera Biologics Inc.ABCL | $75m | 160.6% | −194.9% | −14.5% | 2025 |
| 92 | Recursion Pharmaceuticals, Inc.RXRX | $75m | 26.9% | −863.4% | −59.5% | 2025 |
| 93 | Compugen LTDCGEN | $73m | 161.1% | 48.6% | 44.8% | 2025 |
| 94 | Bicycle Therapeutics PLCBCYC | $73m | 105.8% | −301.7% | −31.2% | 2025 |
| 95 | Assembly Biosciences, Inc.ASMB | $72m | 153.5% | −8.5% | −5.1% | 2025 |
| 96 | Viridian Therapeutics, Inc.\deVRDN | $71m | 23359.9% | −483.6% | −49.2% | 2025 |
| 97 | Black Diamond Therapeutics, Inc.BDTX | $70m | — | 32.0% | 22.9% | 2025 |
| 98 | Vir Biotechnology, Inc.VIR | $69m | −7.6% | −638.9% | −45.7% | 2025 |
| 99 | Intellia Therapeutics, Inc.NTLA | $68m | 16.9% | −609.9% | −53.5% | 2025 |
| 100 | Kura Oncology, Inc.KURA | $67m | 25.2% | −412.9% | −94.8% | 2025 |
| 101 | Spero Therapeutics, Inc.SPRO | $67m | 39.2% | 12.8% | 16.3% | 2025 |
| 102 | Enanta Pharmaceuticals IncENTA | $65m | −3.4% | −125.4% | −84.6% | 2025 |
| 103 | Clinuvel Pharmaceuticals LtdCUVL | $64m | 5.2% | 36.0% | 13.4% | 2026 |
| 104 | Fortress Biotech, Inc.FBIO | $63m | 9.7% | 10.8% | 18.8% | 2025 |
| 105 | Nuvation Bio Inc.NUVB | $63m | 699.0% | −325.3% | −53.2% | 2025 |
| 106 | Tango Therapeutics, Inc.TNGX | $62m | 48.3% | −162.9% | −37.2% | 2025 |
| 107 | Nektar TherapeuticsNKTR | $55m | −43.9% | −297.1% | — | 2025 |
| 108 | Agios Pharmaceuticals, Inc.AGIO | $54m | 48.0% | −764.0% | −30.2% | 2025 |
| 109 | Q32 Bio Inc.QTTB | $54m | — | 55.5% | 125.1% | 2025 |
| 110 | Invivyd, Inc.IVVD | $53m | 110.5% | −98.2% | −34.0% | 2025 |
| 111 | Protalix Biotherapeutics, Inc.PLX | $53m | −1.2% | −12.5% | −14.4% | 2025 |
| 112 | Ocular Therapeutix, IncOCUL | $52m | −18.5% | −511.9% | −54.9% | 2025 |
| 113 | Lexicon Pharmaceuticals, Inc.LXRX | $50m | 60.2% | −101.1% | −39.7% | 2025 |
| 114 | Gossamer Bio, Inc.GOSS | $48m | −57.7% | −351.5% | — | 2025 |
| 115 | Protagonist Therapeutics, IncPTGX | $46m | −89.4% | −282.8% | −20.2% | 2025 |
| 116 | Septerna, Inc.SEPN | $46m | 4174.5% | −106.4% | −12.2% | 2025 |
| 117 | Fennec Pharmaceuticals Inc.FENC | $45m | −6.1% | −21.8% | −65.8% | 2025 |
| 118 | Xilio Therapeutics, Inc.XLO | $44m | 589.9% | −80.1% | −132.5% | 2025 |
| 119 | Wave Life Sciences, Inc.WVE | $43m | −60.5% | −478.3% | −56.2% | 2025 |
| 120 | Coherus Oncology, Inc.CHRS | $42m | 59.8% | 398.4% | — | 2025 |
| 121 | Editas Medicine, Inc.EDIT | $41m | 25.4% | −395.0% | −198.1% | 2025 |
| 122 | Voyager Therapeutics, Inc.VYGR | $40m | −49.5% | −296.5% | −48.3% | 2025 |
| 123 | Kymera Therapeutics, Inc.KYMR | $39m | −16.7% | −794.0% | −25.8% | 2025 |
| 124 | Nanobiotix S.a.NBTX | $37m | −573.6% | −73.5% | — | 2025 |
| 125 | C4 Therapeutics, Inc.CCCC | $36m | 1.0% | −292.1% | −44.4% | 2025 |
| 126 | X4 Pharmaceuticals, IncXFOR | $35m | 1250.5% | −225.6% | −76.0% | 2025 |
| 127 | Bioharvest Sciences Inc.BHST | $35m | 37.0% | −32.3% | −83.2% | 2025 |
| 128 | Precision Biosciences IncDTIL | $34m | −50.1% | −133.4% | −61.5% | 2025 |
| 129 | Verastem, Inc.VSTM | $31m | 209.1% | −677.6% | — | 2025 |
| 130 | Foghorn Therapeutics Inc.FHTX | $31m | 36.8% | −240.3% | — | 2025 |
| 131 | Cue Biopharma, Inc.CUE | $27m | 195.7% | −96.9% | −121.1% | 2025 |
| 132 | Celularity IncCELU | $27m | −51.0% | −345.4% | — | 2025 |
| 133 | Entrada Therapeutics, Inc.TRDA | $25m | −87.9% | −565.5% | −39.1% | 2025 |
| 134 | Metagenomi Therapeutics, Inc.MGX | $25m | −51.8% | −348.5% | −44.7% | 2025 |
| 135 | Alumis Inc.ALMS | $24m | — | −1011.7% | −80.8% | 2025 |
| 136 | Alector, Inc.ALEC | $21m | −79.1% | −679.2% | −181.6% | 2025 |
| 137 | Scynexis IncSCYX | $21m | 449.9% | −41.8% | −16.5% | 2025 |
| 138 | Lenz Therapeutics, Inc.LENZ | $19m | — | −430.3% | −33.6% | 2025 |
| 139 | Proqr Therapeutics N.V.PRQR | $18m | −12.1% | −265.2% | −63.8% | 2025 |
| 140 | Mediwound Ltd.MDWD | $17m | −16.1% | −140.8% | −63.9% | 2025 |
| 141 | Relay Therapeutics, Inc.RLAY | $15m | 53.4% | −1800.6% | −41.1% | 2025 |
| 142 | Lineage Cell Therapeutics, Inc.LCTX | $15m | 53.2% | −436.5% | −103.4% | 2025 |
| 143 | Opus Genetics, Inc.IRD | $14m | 29.1% | −349.3% | — | 2025 |
| 144 | Arbutus Biopharma CorpABUS | $14m | 128.2% | −237.9% | −38.5% | 2025 |
| 145 | Pyxis Oncology, Inc.PYXS | $14m | −14.2% | −574.5% | −91.4% | 2025 |
| 146 | Tonix Pharmaceuticals Holding Corp.TNXP | $13m | 29.8% | −946.2% | −64.5% | 2025 |
| 147 | Evommune, Inc.EVMN | $13m | 85.7% | −529.8% | — | 2025 |
| 148 | Prelude Therapeutics IncPRLD | $12m | 73.4% | −819.6% | −99.5% | 2025 |
| 149 | Mindwalk Holdings Corp.HYFT | $11m | 47.8% | −89.7% | −78.5% | 2026 |
| 150 | Caribou Biosciences, Inc.CRBU | $11m | 11.7% | −1327.4% | −79.0% | 2025 |
| 151 | Crescent Biopharma, Inc.CBIO | $11m | 108340.0% | −1419.6% | −127.5% | 2025 |
| 152 | Tscan Therapeutics, Inc.TCRX | $10m | 266.7% | −1256.8% | −71.3% | 2025 |
| 153 | Alpha Cognition Inc.ACOG | $10m | — | −202.2% | −33.1% | 2025 |
| 154 | Innate Pharma SAIPHA | $10m | −53.2% | −546.1% | — | 2025 |
| 155 | Janux Therapeutics, Inc.JANX | $10m | −5.6% | −1136.3% | −11.5% | 2025 |
| 156 | Zenas Biopharma, Inc.ZBIO | $10m | 100.0% | −3777.4% | −136.2% | 2025 |
| 157 | Taysha Gene Therapies, Inc.TSHA | $10m | 17.3% | −1115.3% | −68.5% | 2025 |
| 158 | Precigen, Inc.PGEN | $10m | 146.7% | −2588.2% | — | 2025 |
| 159 | Curis IncCRIS | $9m | −13.4% | −80.3% | — | 2025 |
| 160 | Bioage Labs, Inc.BIOA | $9m | — | −896.1% | −27.1% | 2025 |
| 161 | Apollomics Inc.APLM | $9m | — | −128.7% | — | 2025 |
| 162 | Roivant Sciences Ltd.ROIV | $8m | −71.6% | −3629.2% | −6.5% | 2026 |
| 163 | Coya Therapeutics, Inc.COYA | $8m | 123.6% | −267.1% | −51.4% | 2025 |
| 164 | Aclaris Therapeutics, Inc.ACRS | $8m | −58.2% | −829.6% | −50.2% | 2025 |
| 165 | Bolt Biotherapeutics, Inc.BOLT | $8m | 0.1% | −433.7% | −79.7% | 2025 |
| 166 | Adagene Inc.ADAG | $8m | 7332.8% | −229.6% | −41.0% | 2025 |
| 167 | Evaxion A/sEVAX | $8m | 125.1% | −102.4% | −100.2% | 2025 |
| 168 | Ovid Therapeutics Inc.OVID | $7m | 1181.3% | −240.1% | −17.5% | 2025 |
| 169 | Whitehawk Therapeutics, Inc.WHWK | $7m | −72.5% | −288.3% | −21.8% | 2025 |
| 170 | Immunome Inc.IMNM | $7m | −23.2% | −3060.0% | −52.1% | 2025 |
| 171 | Fate Therapeutics IncFATE | $7m | −51.2% | −2051.1% | −51.8% | 2025 |
| 172 | Kyntra BIO, Inc.KYNB | $6m | −78.3% | 2848.6% | — | 2025 |
| 173 | Korro Bio, Inc.KRRO | $6m | 181.5% | −1834.5% | −110.7% | 2025 |
| 174 | Abeona Therapeutics Inc.ABEO | $6m | 66.3% | 1223.1% | 81.8% | 2025 |
| 175 | DBV Technologies S.a.DBVT | $6m | 35.8% | −2607.3% | −149.8% | 2025 |
| 176 | Immuron LtdIMRN | $5m | 10.9% | −47.7% | −38.4% | 2026 |
| 177 | Inventiva S.a.IVA | $5m | −49.1% | −7899.6% | — | 2025 |
| 178 | Ensysce Biosciences, Inc.ENSC | $5m | −2.8% | −200.8% | — | 2025 |
| 179 | Adlai Nortye Group Ltd.ANL | $5m | 0.0% | −710.6% | −106.5% | 2025 |
| 180 | Inmed Pharmaceuticals Inc.INM | $5m | 7.5% | −34.4% | −15.0% | 2025 |
| 181 | Prime Medicine, Inc.PRME | $5m | 55.3% | −4342.4% | −146.8% | 2025 |
| 182 | Ocugen, Inc.OCGN | $4m | 8.8% | −1537.4% | — | 2025 |
| 183 | AC Immune SAACIU | $4m | −86.1% | −1971.6% | −94.3% | 2025 |
| 184 | CG Oncology, Inc.CGON | $4m | 254.7% | −3985.0% | −21.7% | 2025 |
| 185 | Cervomed Inc.CRVO | $4m | −58.9% | −673.1% | −93.9% | 2025 |
| 186 | Evogene Ltd.EVGN | $4m | −30.9% | −220.2% | — | 2025 |
| 187 | Marker Therapeutics, Inc.MRKR | $4m | −46.2% | −343.0% | −68.8% | 2025 |
| 188 | Crispr Therapeutics AGCRSP | $4m | −90.6% | −16569.8% | −30.2% | 2025 |
| 189 | Camp4 Therapeutics CorpCAMP | $3m | 436.5% | −2298.5% | −145.1% | 2025 |
| 190 | Surrozen, Inc.SRZN | $3m | −67.4% | −6960.8% | — | 2025 |
| 191 | Dyadic International IncDYAI | $3m | −11.6% | −238.3% | — | 2025 |
| 192 | Xenetic Biosciences, Inc.XBIO | $3m | 19.0% | −90.1% | −40.0% | 2025 |
| 193 | Upstream Bio, Inc.UPB | $3m | 20.4% | −5026.0% | −35.4% | 2025 |
| 194 | Absci CorpABSI | $3m | −38.2% | −4113.7% | −62.5% | 2025 |
| 195 | Cartesian Therapeutics, Inc.RNAC | $3m | −92.8% | −4658.6% | — | 2025 |
| 196 | Geovax Labs, Inc.GOVX | $2m | −37.1% | −862.3% | — | 2025 |
| 197 | Collplant Biotechnologies LtdCLGN | $2m | 360.4% | −484.6% | −117.6% | 2025 |
| 198 | Aligos Therapeutics, Inc.ALGS | $2m | −39.5% | −1106.7% | −196.9% | 2025 |
| 199 | Korsana Biosciences, Inc.KRSA | $2m | 3.7% | −170.1% | −39.3% | 2025 |
| 200 | Humacyte, Inc.HUMA | $2m | — | −2003.6% | — | 2025 |
Other health care industries
- Managed Health Care8 companies
- Health Care Distributors9 companies
- Health Care Services48 companies
- Pharmaceuticals86 companies
- Health Care Equipment153 companies
- Life Sciences Tools & Services60 companies
- Health Care Facilities13 companies
- Hospitals5 companies
- Health Care Supplies13 companies
- Health Care Technology26 companies